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100,000-member health care plan. METHODS: Patient characteristics and AED ef-
ficacy (decrease from baseline in frequency of drop seizures) were modeled with
clinical trial data. Medical costswere derived fromadministrative claims data from
a large US managed health care plan affiliated with OptumInsight, with the as-
sumption that 2.3% of drop seizures required medical care. Budget impact was
measured over 2 years. Results were expressed as overall difference in costs (sei-
zure and pharmacy) to a health plan, and cost permember permonth (PMPM) after
the addition of clobazam. Alternative scenario analyseswere performed.RESULTS:
With the assumption that 0.04 % of the plan population had LGS, addition of clo-
bazam to the formulary resulted in cost savings of $78,600 in Year 1 and $104,000 in
Year 2, corresponding to savings of $0.07 and $0.09 PMPM, respectively. Alternative
analyses with lower seizure rates upon discontinuation or greater long-term effi-
cacy for lamotrigine and topiramate did not substantially alter the conclusion.
Assumption that fewer drop seizures require medical care resulted in a modest
cost increase with clobazam, suggesting that medically attended drop seizures are
a primary driver of costs for LGS patients. CONCLUSIONS:Medically attended drop
seizures are a major cost driver for LGS patients. Our results demonstrate that
adding clobazam to a health care plan formulary can have a positive overall budget
impact through a decrease in medical costs associated with drop seizures.
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OBJECTIVES: To develop a budget impact (BI) and cost-effectiveness (CE) model to
determine the effect of introducing the recently approved once-daily gabapentin
(Gralise™; G-QD) into the existing market of postherpetic neuralgia (PHN)
treatments.METHODS: The BImodel is based on estimated US. PHN incidence and
captures treatment costs from initiation of PHN therapy through sixmonths. Initial
treatments included G-QD, gabapentin TID, and pregabalin. After assessment at 10
weeks, patients could remain on initial monotherapy, or add, switch, or discon-
tinue PHN treatments. Post-assessment therapies also included lidocaine patch
and opioids. Clinical and epidemiological data sources consisted of clinical trial
data, US census data, and published literature. The US payer perspective model
includes direct medical costs (in 2010 US dollars) including pharmacy, physician
visits, and treatment of adverse events. Discounting was excluded due to the short
timeframe. Drugs were priced at wholesale average cost (WAC). Other pricing fac-
tors were co-pays and rebates. Cost sources included proprietary standardized
databases, Medicare fee schedules, and published literature. The CE analysis was
based on a hypothetical 1000-patient cohort. Patientswith andwithout pain reduc-
tion were determined from clinical trial data; outcomes were quality adjusted
based on published PHN utility data for pain and adverse events. Costs were taken
from the BI analysis. RESULTS: For 34,183 PHN patients, the addition of G-QD
decreased the total cost budget by $12,230 (-0.04%). While the pharmacy budget
increased by $299,547 (1.34%), the non-pharmacy budget decreased by $311,777
(-3.06%). In the CE analysis, the incremental cost per quality-adjusted life year was
$31,257 for G-QD versus gabapentin TID, and G-QD dominated pregabalin. Sensi-
tivity analysis demonstrated stable results. CONCLUSIONS: The budget impact of
introducing G-QD to the market is small when considering only pharmacy costs,
but may be cost saving when non-pharmacy costs are included. G-QD is cost-
effective versus other initial PHN treatments.
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OBJECTIVES: Polyethylene glycol-conjugated (PEGylated) therapies are commonly
used to treat patients with anemia, neutropenia, and viral hepatitis. While no
PEGylated drugs are currently approved for the treatment of multiple sclerosis
(MS), a PEGylated formulation of interferon beta-1a is being developed for relaps-
ing-remitting MS treatment. The goal of this study was to identify the economic
benefits of PEGylated drugs currently available in other disease areas.METHODS:A
comprehensive search of the medical literature was conducted using PubMed/
MEDLINE, article links, and supplemental searches. Inclusion criteria included Eng-
lish language, publication date between 1985 and 2010, prospective or retrospective
study design, and cost or cost-effectiveness studies comparing PEGylated drugs
with their non-PEGylated counterparts in the same therapeutic area. All costs were
adjusted to 2010 US dollars for reporting. RESULTS: Thirty-seven published articles
reporting data from 11 countries in 12 therapeutic areas were reviewed, including
studies on pegfilgrastim, liposomal PEGylated doxyrubicin, peginterferon alfa 2a
and 2b, pegaspargase, and PEGylated epoetin. Twelve studies showed some cost
offsets for 6 PEGylated drugs, with 4 of the drugs reducing administration costs.
Other offset costs included those for adverse event treatment, disease complica-
tions, and inpatient/outpatient treatment. Nineteen of the 35 studies considering
total treatment costs showed total cost savingswith 3 of 5 PEGylated drugs, ranging
up to $7743 per patients annually.With 4 PEGylated drugs, 17 of 18 studies reported
incremental cost-effectiveness ratios below $50,000 per quality-adjusted life-year.
CONCLUSIONS: PEGylated drugs are reported to reduce patient health resource use
and costs, including costs associatedwith drug administration and adverse events.
Since multiple studies have demonstrated that PEGylated drugs are more cost-
effective than their non-PEGylated counterparts, PEGylated interferon beta-1amay
offer similar economic benefits to payers and health care systems.
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OBJECTIVES: Little US data are available on the costs of HD, a debilitating disease
marked by motor/cognitive/psychiatric impairment worsening through distinct
disease stages. Our study aimed to quantify the direct health care costs (andmajor
cost drivers) among HD patients by disease stage in commercial (C) versus Medic-
aid (M) databases.METHODS: Health care utilization/cost data (pharmacy, outpa-
tient, inpatient) were obtained for HD patients (ICD-9-CM 333.4) from Thomson
Reuters’ MarketScan M/C 2002-2009 databases. Patients were classified by disease
stage (early/middle/late) via a hierarchical assessment ofmarkers of disease sever-
ity, whichwas confirmed by literature review/key opinion leader input. Health care
utilization/costs were measured over the follow-up time of each patient with total
costs/patient/stage annualized using a patient-year cost approach. RESULTS: A
total of 1272 HD patients (752/520 C/M) were included for this study. The mean age
was similar between the two populations (C: 48.5 years (SD 13.3); M: 49.3 years (SD
17.2)) with slightly higher female representation in the M population (60.8% vs.
54.1%). A fairly even C patient distribution by stage was noted (30.5%/35.5%/34.0%;
early/middle/late). However, most (74.0%) M HD patients were classified as late
stage. Themean total annualized cost per patient varied in both populations (early:
C - $4,947 (SD $6,040), M - $3,257 (SD, $5,670); middle: C - $15,066 (SD $21,722), M -
$12,330 (SD $16,986); late: C - $22,582 (SD $39,028), M - $37,495 (SD $27,111)). Outpa-
tient costs were the primary health care cost component, except for M early stage
(outpatient: early: C – 45.8%; middle: C – 48.2%, M – 66.4%; late: C – 41.5%, M – 78.9%;
inpatient: early: M - 37.7%). Nursing home costs contributed to 54.6% of M but only
4.6% of C total late stage costs. CONCLUSIONS: HD direct health care costs in-
creasedwith disease progression. Late stageM patients had higher costs than their
C counterparts, due to nursing home costs.
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OBJECTIVES: To describe diagnosis codes, frequency and cost of multiple sclerosis
(MS)-related hospital and emergency room (ER) utilization.METHODS:Two cohorts
of MS-diagnosed patients aged 18-64 years were selected from a national managed
care database: 1) longitudinal cohort: patients with 12 months pre/post eligibility
around first MS diagnosis occurring January 1, 2002 to July 30, 2010, and 2) cross-
sectional cohort: patients with an MS diagnosis in 2010. MS-related [multiple scle-
rosis (ICD-9-CM340.XX), other demyelinating CNS disease (ICD-9-CM341.XX),
and a group of symptom-related codes] hospitalizations and ER visits were evalu-
ated. Rehabilitation (ICD-9-CMV57.89) was included based on qualitative review
of codes. Mean number and cost per patient, adjusted to $US 2010, were described.
RESULTS:Therewere 31,905 patients in the longitudinal cohort and 32,845 patients
in the cross-sectional cohort. In the longitudinal cohort, 18.5% had a post-index
hospitalization (any cause) with 5.2% being MS-related (340.XX: 3.2%; 341.XX: 0.4%;
rehabilitation: 0.8%; and symptom-related: 1.1%). Mean number and cost (SD) of an
MS-related hospitalization were 1.19 (0.55) and $14,358 ($32,356), respectively. In
addition, 31.4% of patients experienced a post-index ER visit with 6.9% being MS-
related (340.XX: 2.9%; 341.XX: 0.2%; symptom-related: 4.7%).Meannumber and cost
(SD) of an MS-related ER visit were 1.23 (0.78) and $573 ($816), respectively. In the
cross-sectional cohort, 12.5% had a hospitalization (any cause) with 3.7% being
MS-related (340.XX: 2.1%; 341.XX: 0.2%; rehabilitation: 1.1%; and symptom-related:
0.7%). Mean number and cost (SD) of an MS-related hospitalization were 1.32 (0.78)
and $16,213 ($25,394), respectively. In addition, 27.3% of patients experienced an ER
visit with 6.4% beingMS-related (340.XX: 2.6%; 341.XX: 0.1%; and symptom-related:
4.5%).Meannumber and cost (SD) of anMS-related ER visitwere 1.37 (0.89) and $682
($825), respectively. CONCLUSIONS: Costs for hospitalization and ER visits among
MS patients were substantial. Inclusion of rehabilitation and symptom-related
codes can account for an under-recognized proportion of expenditures.
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OBJECTIVES: Cervical dystonia (CD), or spasmodic torticollis (333.83), is the most
common adult-onset focal dystonia and is associated with significant pain and
disability. The quality of life burden of CD has been well documented; however,
very limited information exists regarding the economic burden of CD. This study
aims to quantify the average per-patient cost of CD health care resource use using
baseline data from the CD Patient Registry for the Observation of Onabotulinum-
toxinA Efficacy (CD PROBE), a large ongoing registry. METHODS: At baseline, par-
ticipants reported use of specific health care resources over the preceding 6
months, including visits to a primary care provider, neurologist, physiatrist, phys-
ical or occupational therapist, neurosurgeon, alternative care provider, chiroprac-
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